**Supplemental Table S2.** *EGFR* testing methods by tissue source tested

|  |  |  |
| --- | --- | --- |
| ***N* (%) of tests** |  | **Tissue source tested** |
| **Testing method** | **Total** | **Primary tumor\*** | **Lymph nodes** | **Metastases\*** | **Unknown source** |
| **n** | **4,200** | **3,436** | **279** | **425** | **60** |
| Direct sequencing | 3,397 (80.9) | 2,816 (82.0) | 226 (81.0) | 316 (74.4) | 39 (65.0) |
| ARMS | 32 (0.8) | 17 (0.5) | 9 (3.2) | 6 (1.4) | 0 (0.0) |
| Other | 170 (4.0) | 135 (3.9) | 6 (2.2) | 25 (5.9) | 4 (6.7) |
| Unknown | 593 (14.1) | 467 (13.6) | 38 (13.6) | 77 (18.1) | 11 (18.3) |
| Data missing | 8 (0.2) | 1 (0.0) | 0 (0.0) | 1 (0.2) | 6 [10.0) |
| **For those patients testing positive for exon 18 and/or 20 mutations** |
| **Testing method** | **Total** | **Primary tumor** | **Lymph nodes** | **Metastases**  | **Unknown source** |
| ***n*** | **70** | **55** | **7** | **7** | **1** |
| Direct sequencing | 60 (85.7) | 48 (87.3) | 5 (71.4) | 6 (85.7) | 1 (100.0) |
| ARMS | 1 (1.4) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 0 (0.0) |
| Other | 2 (2.9) | 1 (1.8) | 0 (0.0) | 1 (14.3) | 0 (0.0) |
| Unknown | 7 (10.0) | 6 (10.9) | 1 (14.3) | 0 (0.0) | 0 (0.0) |
| Data missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

\*Difference in testing method for primary versus (distant) metastatic tissue: *P* = 0.0009 (Fisher’s exact test).

Abbreviation: ARMS, Amplification Refractory Mutation System.